Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide.
Flawless balance sheet with limited growth.
Share Price & News
How has Apyx Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: APYX's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: APYX underperformed the US Medical Equipment industry which returned 5.1% over the past year.
Return vs Market: APYX underperformed the US Market which returned 4.3% over the past year.
Price Volatility Vs. Market
How volatile is Apyx Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 months ago | Simply Wall StApyx Medical Corporation Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.75
8 months ago | Simply Wall StUpdate: Apyx Medical (NASDAQ:APYX) Stock Gained 61% In The Last Five Years
9 months ago | Simply Wall StCan We See Significant Insider Ownership On The Apyx Medical Corporation (NASDAQ:APYX) Share Register?
Is Apyx Medical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate APYX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate APYX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: APYX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: APYX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APYX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APYX is good value based on its PB Ratio (2.6x) compared to the US Medical Equipment industry average (3.8x).
How is Apyx Medical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APYX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APYX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APYX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APYX's revenue (39% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: APYX's revenue (39% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APYX's Return on Equity is forecast to be high in 3 years time
How has Apyx Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APYX is currently unprofitable.
Growing Profit Margin: APYX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APYX is unprofitable, and losses have increased over the past 5 years at a rate of -44.1% per year.
Accelerating Growth: Unable to compare APYX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APYX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.4%).
Return on Equity
High ROE: APYX has a negative Return on Equity (-22.79%), as it is currently unprofitable.
How is Apyx Medical's financial position?
Financial Position Analysis
Short Term Liabilities: APYX's short term assets ($74.2M) exceed its short term liabilities ($10.6M).
Long Term Liabilities: APYX's short term assets ($74.2M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: APYX's debt to equity ratio (0.2%) is considered satisfactory.
Reducing Debt: APYX's debt to equity ratio has reduced from 12.8% to 0.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APYX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: APYX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 42.8% each year.
What is Apyx Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APYX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APYX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APYX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APYX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Charlie Goodwin (54yo)
Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves ...
CEO Compensation Analysis
Compensation vs Market: Charlie's total compensation ($USD1.95M) is above average for companies of similar size in the US market ($USD1.34M).
Compensation vs Earnings: Charlie's compensation has increased whilst the company is unprofitable.
|CFO, Treasurer & Secretary||1.5yrs||US$700.00k||no data|
|Senior Vice President||8.5yrs||US$721.36k||1.19% $2.2m|
|Executive Vice President||1.5yrs||US$892.26k||no data|
Experienced Management: APYX's management team is considered experienced (2 years average tenure).
|Independent Chairman of the Board||6.58yrs||US$139.87k||1.78% $3.2m|
|Independent Director||9.33yrs||US$129.87k||no data|
|Lead Independent Director||9.33yrs||US$218.37k||no data|
|Member of Scientific Advisory Board||no data||US$9.30k||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Independent Vice-Chairman of the Board||6yrs||US$157.37k||no data|
|Independent Director||0.92yr||US$97.37k||no data|
|Independent Director||2.33yrs||US$119.87k||0.13% $239.5k|
|Member of Medical Advisory Board||3.5yrs||no data||no data|
Experienced Board: APYX's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: APYX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Apyx Medical Corporation's company bio, employee growth, exchange listings and data sources
- Name: Apyx Medical Corporation
- Ticker: APYX
- Exchange: NasdaqGS
- Founded: 1982
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$181.176m
- Shares outstanding: 34.18m
- Website: https://apyxmedical.com
Number of Employees
- Apyx Medical Corporation
- 5115 Ulmerton Road
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|APYX||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Jul 1983|
|BOV||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jul 1983|
Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company’s Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the J-Plasma system allows surgeons to operate in eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/02 00:12|
|End of Day Share Price||2020/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.